Design and Preclinical Evaluation of a Novel Prostate-Specific Membrane Antigen Radioligand Modified with a Transthyretin Binder

Christian Vaccarin,Ana Katrina Mapanao,Luisa M. Deberle,Anna E. Becker,Francesca Borgna,Giovanni Marzaro,Roger Schibli,Cristina Müller

DOI: https://doi.org/10.3390/cancers16071262

2024-03-24

Cancers

Abstract:Transthyretin binders have previously been used to improve the pharmacokinetic properties of small-molecule drug conjugates and could, thus, be utilized for radiopharmaceuticals as an alternative to the widely explored "albumin binder concept". In this study, a novel PSMA ligand modified with a transthyretin-binding entity (TB-01) was synthesized and labeled with lutetium-177 to obtain [177Lu]Lu-PSMA-TB-01. A high and specific uptake of [177Lu]Lu-PSMA-TB-01 was found in PSMA-positive PC-3 PIP cells (69 ± 3% after 4 h incubation), while uptake in PSMA-negative PC-3 flu cells was negligible (<1%). In vitro binding studies showed a 174-fold stronger affinity of [177Lu]Lu-PSMA-TB-01 to transthyretin than to human serum albumin. Biodistribution studies in PC-3 PIP/flu tumor-bearing mice confirmed the enhanced blood retention of [177Lu]Lu-PSMA-TB-01 (16 ± 1% IA/g at 1 h p.i.), which translated to a high tumor uptake (69 ± 13% IA/g at 4 h p.i.) with only slow wash-out over time (31 ± 8% IA/g at 96 h p.i.), while accumulation in the PC-3 flu tumor and non-targeted normal tissue was reasonably low. Further optimization of the radioligand design would be necessary to fine-tune the biodistribution and enable its use for therapeutic purposes. This study was the first of this kind and could motivate the use of the "transthyretin binder concept" for the development of future radiopharmaceuticals.

oncology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is: how to improve the pharmacokinetic properties of prostate - specific membrane antigen (PSMA) - targeted radioligands to increase their accumulation in tumor tissues, thereby enhancing the treatment effect on metastatic prostate cancer.

Specifically, the researchers developed a new small - molecule PSMA radioligand and modified it with a transthyretin binder (TB - 01). This new ligand was labeled with lutetium - 177 ([177Lu]Lu - PSMA - TB - 01), aiming to prolong its circulation time in the blood and thus increase the tumor uptake. The experimental results showed that, compared with the clinically commonly used [177Lu]Lu - PSMA - 617, the new radioligand has a longer retention time in the blood, a significant increase in active accumulation in tumor tissues, while the retention in non - targeted tissues remains at the same level or only slightly increases in the kidneys.

The following are the key issues and goals of this study:

1. **Increase tumor uptake**: Enhance the circulation time of small - molecule radioligands in the blood by introducing transthyretin binders, thereby increasing their accumulation in tumor tissues.
2. **Optimize pharmacokinetics**: Study the influence of transthyretin binders on the pharmacokinetics of radioligands, and evaluate their distribution and clearance in vivo.
3. **Verify binding affinity**: Determine the binding affinity of the new ligand to transthyretin and human serum albumin to ensure that it has the expected biodistribution characteristics.
4. **Compare clinical application potential**: Compare the new ligand with the existing clinically used radioligands (such as [177Lu]Lu - PSMA - 617) to evaluate its advantages as a potential therapeutic drug.

In summary, this study aims to explore a new strategy, that is, using transthyretin binders to improve the pharmacokinetic properties of PSMA - targeted radioligands, in the hope of providing a more effective tool for the treatment of metastatic prostate cancer.